TrialJAMA neurology2017

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.

David Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.